Using advanced MRI to study brain lymphoma treatment responses
Application of Hyperpolarized 13C Magnetic Resonance Imaging to Detect Target Inhibition of NF-kB Activation and Response in Primary CNS Lymphoma
This study is looking at a new imaging method to see how a specific cancer pathway works in primary CNS lymphoma, a tough type of brain cancer, so that doctors can find better treatment options and improve outcomes for patients like you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-10651730 on NIH RePORTER |
What this research studies
This research focuses on using a cutting-edge imaging technique called hyperpolarized 13C MRI to investigate how a specific cancer pathway, NF-kB, is activated in primary CNS lymphoma, a challenging type of brain cancer. By monitoring metabolic changes in the tumor, the researchers aim to better understand how the cancer responds to treatments that target NF-kB. This approach could help identify effective combinations of therapies and biomarkers that predict treatment success, ultimately improving patient outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with primary CNS lymphoma who are undergoing treatment.
Not a fit: Patients with other types of brain tumors or those not diagnosed with primary CNS lymphoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment strategies for patients with primary CNS lymphoma.
How similar studies have performed: Previous studies have shown promising results using similar imaging techniques in other types of brain tumors, indicating potential for success in this novel application.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Rubenstein, James Louis — University of California, San Francisco
- Study coordinator: Rubenstein, James Louis
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.